Anzeige
Erschienen in:
01.06.2015 | Original Article
Moxibustion for the treatment of chemotherapy-induced leukopenia: a systematic review of randomized clinical trials
Erschienen in: Supportive Care in Cancer | Ausgabe 6/2015
Einloggen, um Zugang zu erhaltenAbstract
Purpose
The purpose of this study is to assess the efficacy of moxibustion as a treatment of chemotherapy-induced leukopenia.
Methods
Twelve databases were searched from their inception through June 2014, without a language restriction. Randomized clinical trials (RCTs) were included if moxibustion was used as the sole treatment or as a part of a combination therapy with conventional drugs for leukopenia induced by chemotherapy. Cochrane criteria were used to assess the risk of bias.
Results
Six RCTs with a total of 681 patients met our inclusion criteria. All of the included RCTs were associated with a high risk of bias. The trials included patients with various types of cancer receiving ongoing chemotherapy or after chemotherapy. The results of two RCTs suggested the effectiveness of moxibustion combined with chemotherapy vs. chemotherapy alone. In four RCTs, moxibustion was more effective than conventional drug therapy. Six RCTs showed that moxibustion was more effective than various types of control interventions in increasing white blood cell counts.
Conclusions
There is low level of evidence based on these six trials that demonstrates the superiority of moxibustion over drug therapies in the treatment of chemotherapy-induced leukopenia. However, the number of trials, the total sample size, and the methodological quality are too low to draw firm conclusions. Future RCTs appear to be warranted.